

Press Release

Protagen counts on Scienion Technology

Dortmund and Berlin, Germany, April 19, 2011: Scienion AG today announced that the company will produce protein microarray batches for clinical validation studies of proprietary biomarker panels of Protagen AG. The batch sizes will comprise more than 1000 arrays. Additionally, both companies plan to jointly evaluate new platforms for multiplex analytics and to co-develop novel approaches up to proof-of-concept levels under a strategic partnership.

“For the multicenter, international clinical validation studies of our multiplex diagnostic markers for the early detection of multiple sclerosis and the differential diagnosis of prostate cancer it is essential to ensure a consistently high statistical reliability for diagnostic conclusions. Scienion’s sciFLEXARRAYER technology – worldwide leading in nanodispensing – allows the manufacturing of protein microarray batches each with more than 3500 single proteins in highest quality and reproducibility”, comments Dr. Peter Schulz-Knappe, CSO of Protagen AG. “Thereby, we can realize the needed consistency in quality and properties throughout three stages: from spot to spot, from array to array and from batch to batch.”

“We are very pleased to welcome Protagen as a customer and partner for joint developments. The leading position of Protagen in providing high quality content for protein microarrays, and the UNlarray[®] concept for the development and validation of multiplex markers offers Scienion the possibility to perform feasibility studies close to the market and thus to demonstrate Scienion’s capacity and efficiency to new customers from the diagnostics and pharma industry“, states Dr. Holger Eickhoff, CEO of Scienion AG.

About Protagen AG

Protagen AG (www.protagen.de) is an international leading specialist in the fields of in-vitro diagnostics and GMP-compliant protein analysis. The innovations of Protagen are UNlarray[®], a technology platform for the development of novel serum based diagnostics, as well as UNlchip[®], a versatile product family of protein microarrays for faster development of antibodies.

About Scienion

Scienion AG provides systems and services for the contact-free printing of biological and chemical agents for diagnostics, pharmaceuticals, veterinary, plant and food analytics and research. Addressing the dynamically increasing needs for miniaturization and multiplex analyses, Scienion offers a unique technology portfolio that has been consequently expanded over one decade. Scienion provides flexible solutions for research and development whereas solutions for production purposes are rather customized. Systems and software are characterized by its versatility, precision and robustness. The company is a renowned specialist for ultra low volume liquid handling, particularly for the handling of precious and sensitive compounds of biological or chemical origin. Scienion’s dispensers allow for contact-free and precise drop spotting in the pico- to nano-liter range and are optimally suited for microarray based analytics – as for tests with DNA, oligonucleotides, peptides, proteins, antibodies, glycans or for dispensing cells onto various carriers. The company operates from two sites, Dortmund and Berlin.

Contact Protagen AG

Dr. Stefan Müllner
CEO
Protagen AG
Otto-Hahn-Str. 15
44227 Dortmund

Tel: +49 (0) 231 9742 6300
Fax: +49 (0) 231 9742 6301
E-Mail: info@protagen.de

Contact Scienion AG

SCIENION AG
Almut Gebhard
Otto-Hahn-Str. 15
D-44227 Dortmund
Phone +49 (0)30 - 6392 1700
Fax: +49 (0)30 - 6392 1701
gebhard@scienion.com
www.scienion.com

Media Inquiries

Bettina Franz
Protagen AG
Otto-Hahn-Str. 15
44227 Dortmund

Tel: +49 (0) 231 9742 6300
Fax: +49 (0) 231 9742 6301
E-Mail: bettina.franz@protagen.de